• Save
Pieter Jelle Visser
Upcoming SlideShare
Loading in...5
×
 

Pieter Jelle Visser

on

  • 3,295 views

 

Statistics

Views

Total Views
3,295
Views on SlideShare
1,146
Embed Views
2,149

Actions

Likes
0
Downloads
0
Comments
0

5 Embeds 2,149

http://www.alzforum.org 2138
http://translate.googleusercontent.com 7
http://brfroot.prod.acquia-sites.com 2
http://webcache.googleusercontent.com 1
http://alzforum.org 1

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Pieter Jelle Visser Pieter Jelle Visser Presentation Transcript

  • Comparison of International Working Group and NIA-AA criteria for Alzheimer’s disease Pieter Jelle Visser, MD, PhD Alzheimer centre, MeHNS, Department of Psychiatry, University of Maastricht Maastricht Alzheimer center, Department of Neurology, VUMC, Amsterdam The Netherlands
  • IWG versus NIA-AA• Approach• Terminology• Cognitive criteria• Biomarker criteria• Challenges ahead
  • Approach IWG NIA-AA Normal Normal ADAD MCI MCI AD Dementia Dementia AD View slide
  • TerminologyAsymptomatic stage Symptomatic stage AD-SCI AD-MCI stage AD-dementia stage stage Visser et al in preparation View slide
  • Terminology Asymptomatic stage Symptomatic stage AD-SCI AD-MCI stage AD-dementia stage stage Asymptomatic at risk ? Prodromal AD AD dementiaIWG for AD AD (typical/atypical)
  • Terminology Asymptomatic stage Symptomatic stage AD-SCI AD-MCI stage AD-dementia stage stage Asymptomatic at risk ? Prodromal AD AD dementia IWG for AD AD (typical/atypical) Preclinical AD MCI due to AD Dementia due toNIA-AA Stages 1-2 Stage 3 AD
  • Cognitive criteria IWG NIA-AA Memory - MCICognition Cognition impairment - Dementia
  • Biomarker criteria NIA-AA Amyloid Injury CSF Abeta 42 Tau, p-tau sMRI - Hippocampal atrophyIWG PET Amyloid FDG - SPECT
  • Biomarker criteria NIA-AA Amyloid Injury CSF Abeta 42 Tau, p-tau sMRI - Hippocampal atrophyIWG PET Amyloid FDG - SPECT
  • Biomarker criteria IWG NIA-AA Amyloid Injury High + + Intermediate + ?Amyloid or injury markers ? + Uninformative + - - + Low - -
  • Biomarker criteria IWG NIA-AA Amyloid Injury High + + Intermediate + ?Amyloid or injury markers ? + Uninformative + - - + Low - -
  • Biomarker criteria IWG NIA-AA Amyloid Injury High + + Intermediate + ?Amyloid or injury markers ? + Uninformative + - - + Low - -
  • Biomarker criteria IWG NIA-AA Amyloid Injury High + + Intermediate + ?Amyloid or injury markers ? + Uninformative + - - + Low - -
  • Biomarker criteria IWG NIA-AA Amyloid Injury High + + Intermediate + ?Amyloid or injury markers ? + Uninformative + - - + Low - -
  • IWG versus NIA-AA IWG NIA-AA• Strengths • Strengths – Disease driven – Broad MCI definition – Takes into account availability biomarkers – Hierarchy biomarkers recognized• Limitations • Limitations – No hierarchy biomarkers – Position amyloid in – Prodromal AD term biomarker hierarchy – 3 different criteria
  • Challenges• Conflicting biomarkers• Standardization and cut-points• Validation• From diagnosis to prognosis